Gilead Sciences, Inc.
GILD
Jodie situation report
Gilead Sciences, Inc.'s move is being confirmed by its market group.
GILD accounts for 9.8% of the group's measured movement across 7.8 effective names. raw member direction is mixed; 6 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
No material onset for GILD could be timestamped inside the aligned 5-minute window.
- Revenue increased 4.4% versus the comparable filing period.
8 of 15 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.
- At least 10 of 15 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ABBV begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Who this business touches
The relationships behind GILD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
KYMRKymera Therapeutics, Inc.partnerFeb 24, 2026 ▾
“Entered into an exclusive option and license agreement with Kymera Therapeutics, Inc.”
RCUSArcus Biosciences, Inc.investeeMay 7, 2026 ▾
“For equity investments in our strategic partners, such as in connection with our collaborations with Arcus Biosciences, Inc.”
Depended on by
ASMBAssembly Biosciences, Inc.partnerMay 7, 2026 ▾
“In addition, our collaboration with Gilead also brings us an industry-leading partner and brings together the teams’ expertise in virology and provides an established partner for late-stage development and commercialization.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 35 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
GILD is currently a Follower in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.